Q-omics provides the consensus-scored CLCP2 profile across patient tissues and cancer cell-line models. CLCP2 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in DLBC. Among the 18 cancer types available for tumor–normal comparison, CLCP2 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, CLCP2 RNA expression shows 13,461 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight DLBC, THCA, and THYM as cancer lineages where CLCP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLCP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLCP2 survival associations across molecular data types. CLCP2 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLCP2 RNA expression–survival associations across cancer types. High CLCP2 expression shows unfavorable associations in DLBC, LUSC, UVM and OV, but favorable associations in KIRP and TGCT. The DLBC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify DLBC as the clearest survival context for CLCP2 RNA expression.
This table summarizes CLCP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CLCP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLCP2 shows lower tumor expression in THCA, KIRC, KIRP, LUSC, KICH and UCEC. The THCA box plot shows higher CLCP2 RNA expression in normal versus tumor tissue (log2 FC = −0.514, t-test p < 0.001).
This table shows molecular features associated with CLCP2 in patient tissues and cancer cell lines. In patient samples, CLCP2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
